Sucampo Pharmaceuticals
| Public | |
| Traded as | NASDAQ: SCMP |
| Industry | Pharmaceutical |
| Founded | 1996 |
| Headquarters | Bethesda, Maryland |
| Products | Amitiza |
| Website |
sucampo |
Sucampo Pharmaceuticals, Inc. is a public, American biopharmaceutical company focused on medical applications of a class of ion channel modulators called prostones.[1][2]
Products
Sucampo has two marketed products, Amitiza and Rescula.[3] As of 2014, Takeda distributes this drug globally except for in Japan and China.[4]
Corporate governance
The company's chief financial officer, as of 2014, was Cary J. Claiborne.[5]
References
- ↑ "SCMP—News and Analysis—Sucampo Pharmaceuticals, Inc.". Seeking Alpha. Company description. Retrieved 1 January 2015.
- ↑ Brewer, Jim (31 December 2014). "Sucampo Pharmaceuticals Hits New 12-Month High at $14.90 (SCMP)". WKRB News. WKRB.
- ↑ Staff (5 December 2014). "Sucampo Pharmaceuticals (SCMP): New Analyst Report from Zacks Equity Research - Zacks Equity Research Report".
- ↑ House, Douglas W. (31 December 2014). "Canada accepts Sucampo's NDS for constipation med". Seeking Alpha.
- ↑ Pearson, Nolan (30 December 2014). "Maxim Group Raises Sucampo Pharmaceuticals Price Target to $15.00". WKRB News. WKRB.
This article is issued from Wikipedia - version of the 2/23/2015. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.